Zack Lynch is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT,Center for Cognitive Liberty & Ethics, the InnerSpace Foundation, the Center for Neuroeconomic Studies and SocialText, a social software company. His book on how brain science is changing our world will be available July 2009. Please send newsworthy items or feedback - to Zack Lynch.
Sound Pharmaceuticals researchers are quickly moving forward on developing neuroceuticals to stem hearing loss. Hearing loss is the third leading chronic disorder and exceeds the number of persons with either diabetes or visual loss combined.
"According to the NIH, CDC and NIOSH, hearing loss is the most common neurosensory disorder and the most common occupational disease. Hearing loss is found in all age groups and can seriously compromise the quality of life or job performance of those affected.
Hair cell regeneration to improve or restore hearing in persons with permanent hearing loss is a significant product pipeline for Sound Pharmaceuticals, Inc. SPI previously announced that its patent, Method for the treatment of diseases or disorders of the inner ear, was issued in Europe, effective Oct. 1, 2003."
(disclaimer: Eric Lynch, VP of Research, is my brother).
Yes you have stated your position quite clearly in my opinion
Permalink to Comment
About Us |
Contact Us |
RSS |
Advertise |
© Copyright 2000-2006 Corante. All rights reserved.
